Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
Status:
Terminated
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of oblimersen when given
together with doxorubicin and docetaxel and to see how well they work in treating women with
metastatic or locally advanced breast cancer. Drugs used in chemotherapy, such as doxorubicin
and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing
or die. Oblimersen may increase the effectiveness of doxorubicin and docetaxel by making the
tumor cells more sensitive to the drugs.